Preferred Label : Anti-PD-L1/Anti-4-1BB Bispecific Antibody ABL503;
NCIt synonyms : PD-L1x4-1BB Bispecific Antibody ABL503; Anti-PD-L1/4-1BB Bispecific Antibody ABL503; Anti-PD-L1/CD137 Bispecific Antibody ABL503;
NCIt definition : A bispecific antibody composed of a Fc-silenced human immunoglobulin G1 (IgG1) monoclonal
antibody targeting human programmed death-ligand 1 (PD-L1) fused with a single chain
variable fragment (scFv) targeting 4-1BB (CD137; tumor necrosis factor receptor superfamily
member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic
activities. Upon administration, anti-PD-L1/anti-4-1BB bispecific antibody ABL503
simultaneously targets and binds to 4-1BB, which is expressed on a variety of leukocyte
subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. Upon
PD-L1 binding, the 4-1BB activation signal is induced and ABL503 acts as a conditional
4-1BB agonist in the tumor microenvironment (TME), resulting in T-cell co-stimulation
and enhances T-lymphocyte-mediated anti-tumor activity. At the same time, ABL503 prevents
PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1;
PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific
T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead
to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits
the expansion and survival of CD8-positive T-cells, suppresses the immune system and
results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor
receptor superfamily, is an inducible costimulatory receptor that plays a key role
in T-cell proliferation, survival and cytolytic activity.;
Molecule name : ABL-503; ABL 503;
NCI Metathesaurus CUI : CL1662155;
Origin ID : C179637;
UMLS CUI : C5555832;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
